- CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Egan, L.J., Myhre, G.M., Mays, D.C., Dierkhising, R.A., Kammer, P.P., Murray, J.A. Aliment. Pharmacol. Ther. (2003)